BeiGene (BGNE) Revenue & Revenue Breakdown
BeiGene Revenue Highlights
Latest Revenue (Y)
$2.46B
Latest Revenue (Q)
$929.17M
Main Segment (Y)
Collaboration
Main Geography (Y)
UNITED STATES
BeiGene Revenue by Period
BeiGene Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.46B | 73.65% |
| 2022-12-31 | $1.42B | 20.37% |
| 2021-12-31 | $1.18B | 280.83% |
| 2020-12-31 | $308.87M | -27.87% |
| 2019-12-31 | $428.21M | 116.03% |
| 2018-12-31 | $198.22M | -16.85% |
| 2017-12-31 | $238.39M | 22179.16% |
| 2016-12-31 | $1.07M | -87.86% |
| 2015-12-31 | $8.82M | -32.37% |
| 2014-12-31 | $13.04M | 16.93% |
| 2013-12-31 | $11.15M | - |
BeiGene generated $2.46B in revenue during NA 2023, up 73.65% compared to the previous quarter, and up 1240.43% compared to the same period a year ago.
BeiGene Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $929.17M | 23.62% |
| 2024-03-31 | $751.65M | 18.48% |
| 2023-12-31 | $634.41M | -18.80% |
| 2023-09-30 | $781.31M | 31.25% |
| 2023-06-30 | $595.26M | 32.93% |
| 2023-03-31 | $447.80M | 17.81% |
| 2022-12-31 | $380.10M | -1.94% |
| 2022-09-30 | $387.63M | 13.48% |
| 2022-06-30 | $341.57M | 11.40% |
| 2022-03-31 | $306.63M | 43.30% |
| 2021-12-31 | $213.98M | 3.65% |
| 2021-09-30 | $206.44M | 37.63% |
| 2021-06-30 | $149.99M | -75.24% |
| 2021-03-31 | $605.87M | 505.27% |
| 2020-12-31 | $100.10M | 9.90% |
| 2020-09-30 | $91.08M | 38.77% |
| 2020-06-30 | $65.64M | 26.08% |
| 2020-03-31 | $52.06M | -8.50% |
| 2019-12-31 | $56.89M | 13.46% |
| 2019-09-30 | $50.14M | -79.40% |
| 2019-06-30 | $243.35M | 212.65% |
| 2019-03-31 | $77.83M | 32.66% |
| 2018-12-31 | $58.67M | 8.24% |
| 2018-09-30 | $54.20M | 2.65% |
| 2018-06-30 | $52.80M | 62.25% |
| 2018-03-31 | $32.54M | 79.07% |
| 2017-12-31 | $18.17M | -91.75% |
| 2017-09-30 | $220.21M | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $137.13M | 100.00% |
| 2016-09-30 | - | -100.00% |
| 2016-06-30 | $393.00K | -41.95% |
| 2016-03-31 | $677.00K | -85.52% |
| 2015-12-31 | $4.68M | 238.91% |
| 2015-09-30 | $1.38M | - |
| 2015-06-30 | $1.38M | 0.07% |
| 2015-03-31 | $1.38M | -0.14% |
| 2014-12-31 | $1.38M | -78.74% |
| 2014-09-30 | $6.50M | - |
BeiGene generated $929.17M in revenue during Q2 2024, up 23.62% compared to the previous quarter, and up 207.50% compared to the same period a year ago.
BeiGene Revenue Breakdown
BeiGene Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| License | $71.98M | $71.98M | $484.65M | - | - |
| Collaboration Research And Development Service | $79.43M | $53.67M | - | $27.98M | - |
| Collaboration Other | $213.45M | $213.45M | - | - | $150.00M |
| Right To Access Intellectual Property Revenue | $104.48M | $3.98M | - | - | - |
| Collaboration | $268.93M | $161.31M | - | $205.62M | - |
| Collaboration Reimbursement Of Research And Development Costs | - | - | - | - | $27.63M |
| License Revenue | - | - | - | - | - |
BeiGene's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration (36.43%), Collaboration Other (28.91%), Right To Access Intellectual Property Revenue (14.15%), Collaboration Research And Development Service (10.76%), and License (9.75%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Right To Access Intellectual Property Revenue | - | $52.50M | $51.98M | $26.25M | $26.25M | $26.25M | $26.25M | $26.25M | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration Other | $4.73M | - | $213.45M | $213.45M | $213.45M | $213.45M | $213.45M | $213.45M | - | - | - | - | $150.00M | - | - | - | - | - | - | - |
| Collaboration Research And Development Service | - | $20.38M | $59.05M | $13.56M | $6.82M | $9.83M | $10.81M | $13.43M | $13.98M | $11.37M | $15.11M | - | - | - | - | - | $25.74M | - | - | - |
| Collaboration | $4.73M | $189.90M | $41.52M | $41.07M | $38.12M | $37.06M | $45.05M | - | - | - | - | - | $185.20M | - | - | - | - | - | - | - |
| License | - | - | $71.98M | $71.98M | $71.98M | $71.98M | $71.98M | $71.98M | - | - | $484.65M | - | - | - | - | - | - | - | - | - |
| Product | - | - | - | - | - | $339.02M | $54.22M | $100.10M | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration Reimbursement Of Research And Development Costs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $9.46M |
BeiGene's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Collaboration Other (50.00%), and Collaboration (50.00%).
BeiGene Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| CHINA | $1.10B | $840.03M | $517.17M | $290.65M | $221.56M |
| Europe | $202.01M | - | - | - | - |
| UNITED STATES | $1.13B | $18.23M | $134.69M | - | - |
| All Other Countries Except China And United States Of America | $28.98M | $73.26M | $163.84M | - | $71.97M |
BeiGene's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (45.84%), CHINA (44.77%), Europe (8.21%), and All Other Countries Except China And United States Of America (1.18%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe | $66.86M | $116.43M | $85.58M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| CHINA | $320.38M | $271.33M | $287.94M | $295.78M | $246.91M | $233.27M | $212.43M | $190.74M | $158.78M | $122.64M | $95.98M | $91.34M | $85.38M | $62.58M | $51.34M | $55.85M | $50.14M | $58.14M | $57.42M | $38.45M |
| All Other Countries Except China And United States Of America | $12.96M | - | $9.56M | $47.13M | $35.87M | $19.57M | $14.82M | $16.47M | $4.19M | $3.51M | $149.93M | - | - | - | - | - | $64.82M | $7.14M | $5.51M | - |
| UNITED STATES | $351.46M | $477.64M | $398.23M | $252.35M | $8.76M | $5.70M | $3.06M | $717.00K | $1.04M | - | $120.38M | $13.27M | $10.24M | - | - | - | - | - | - | - |
BeiGene's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (46.76%), CHINA (42.62%), Europe (8.90%), and All Other Countries Except China And United States Of America (1.72%).
BeiGene Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INCY | Incyte | $3.70B | $962.99M |
| BGNE | BeiGene | $2.46B | $929.17M |
| BMRN | BioMarin Pharmaceutical | $2.42B | $733.87B |
| IONS | Ionis Pharmaceuticals | $787.65M | $225.00M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| ARWR | Arrowhead Pharmaceuticals | $240.74M | - |
| TVTX | Travere Therapeutics | $145.24M | $62.90M |
| KRYS | Krystal Biotech | $50.70M | $83.84M |
| IMAB | I-Mab | $27.64M | $1.10M |
| RXDX | Prometheus Biosciences | $6.81M | $1.10M |
| PCVX | Vaxcyte | - | - |
| IMVT | Immunovant | - | - |
| AKRO | Akero Therapeutics | - | - |
BGNE Revenue FAQ
What is BeiGene’s yearly revenue?
BeiGene's yearly revenue for 2023 was $2.46B, representing an increase of 73.65% compared to 2022. The company's yearly revenue for 2022 was $1.42B, representing an increase of 20.37% compared to 2021. BGNE's yearly revenue for 2021 was $1.18B, representing an increase of 280.83% compared to 2020.
What is BeiGene’s quarterly revenue?
BeiGene's quarterly revenue for Q2 2024 was $929.17M, a 23.62% increase from the previous quarter (Q1 2024), and a 56.09% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $751.65M, a 18.48% increase from the previous quarter (Q4 2023), and a 67.85% increase year-over-year (Q1 2023). BGNE's quarterly revenue for Q4 2023 was $634.41M, a -18.80% decrease from the previous quarter (Q3 2023), and a 66.91% increase year-over-year (Q4 2022).
What is BeiGene’s revenue growth rate?
BeiGene's revenue growth rate for the last 3 years (2021-2023) was 109.03%, and for the last 5 years (2019-2023) was 474.20%.
What are BeiGene’s revenue streams?
BeiGene's revenue streams in c 23 are License, Collaboration Research And Development Service, Collaboration Other, Right To Access Intellectual Property Revenue, and Collaboration. License generated $71.98M in revenue, accounting 9.75% of the company's total revenue Collaboration Research And Development Service generated $79.43M in revenue, accounting 10.76% of the company's total revenue, up 48.00% year-over-year. Collaboration Other generated $213.45M in revenue, accounting 28.91% of the company's total revenue Right To Access Intellectual Property Revenue generated $104.48M in revenue, accounting 14.15% of the company's total revenue, up 2525.71% year-over-year. Collaboration generated $268.93M in revenue, accounting 36.43% of the company's total revenue, up 66.72% year-over-year.
What is BeiGene’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of BeiGene was Collaboration. This segment made a revenue of $268.93M, representing 36.43% of the company's total revenue.